Literature DB >> 16732726

The role of beta1 integrin subfamily in anchorage-dependent apoptosis of breast carcinoma cells differing in multidrug resistance.

G E Morozevich1, N I Kozlova, M E Preobrazhenskaya, N A Ushakova, I A Eltsov, A A Shtil, A E Berman.   

Abstract

Integrin expression was investigated in MCF-7 human breast adenocarcinoma line and in the MCF-7Dox line, which was selected from MCF-7 by a resistance to multiple antitumor drugs (MDR). We have shown that acquisition of MDR was accompanied by a drastically reduced expression of some integrins of the beta1-subfamily (alpha2beta1, alpha3beta1, alpha6beta1) and of alpha vbeta5 intergin in the adenocarcinoma cells. In contrast, expression of alpha5beta1 integrin was markedly increased in the MDR cells. Along with multiple antitumor drug resistance, MCF-7Dox cells demonstrate elevated resistance to anchorage-dependent apoptosis (anoikis) and enhanced in vitro invasive activity. To elucidate the implication of beta1-integrins in the above phenotypic modifications, the effect of beta1-integrin signaling was assayed. Stimulation of beta1-mediated signaling was accomplished by treating of the cells with antibodies to the beta1-subunit common for members of the beta1-subfamily. These data show that activation of beta1-integrin signaling markedly upregulated anoikis of the adenocarcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16732726     DOI: 10.1134/s000629790605004x

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  6 in total

1.  Identification of subtilase cytotoxin (SubAB) receptors whose signaling, in association with SubAB-induced BiP cleavage, is responsible for apoptosis in HeLa cells.

Authors:  Kinnosuke Yahiro; Mamoru Satoh; Naoko Morinaga; Hiroyasu Tsutsuki; Kohei Ogura; Sayaka Nagasawa; Fumio Nomura; Joel Moss; Masatoshi Noda
Journal:  Infect Immun       Date:  2010-11-22       Impact factor: 3.441

2.  The mojastin mutant Moj-DM induces apoptosis of the human melanoma SK-Mel-28, but not the mutant Moj-NN nor the non-mutated recombinant Moj-WN.

Authors:  Agustin I Seoane; Victoria L Tran; Elda E Sanchez; Stephanie A White; Jason L Choi; Brandon Gaytán; Natalie Chavez; Steven R Reyes; Carla J Ramos; Luan H Tran; Sara E Lucena; Maria Sugarek; John C Perez; Stephanie A Mandal; Shervin Ghorab; Alexis Rodriguez-Acosta; Branden K Fung; Julio G Soto
Journal:  Toxicon       Date:  2010-04-14       Impact factor: 3.033

3.  Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts.

Authors:  Catherine C Park; Hui J Zhang; Evelyn S Yao; Chong J Park; Mina J Bissell
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

4.  Novel monoclonal antibody against beta 1 integrin enhances cisplatin efficacy in human lung adenocarcinoma cells.

Authors:  Min-Young Kim; Woon-Dong Cho; Kwon Pyo Hong; Da Bin Choi; Jeong Won Hong; Soseul Kim; Yoo Ri Moon; Seung-Myoung Son; Ok-Jun Lee; Ho-Chang Lee; Hyung Geun Song
Journal:  J Biomed Res       Date:  2016-04-20

5.  rLj-RGD3, a Novel Three-RGD-Motif-Containing Recombinant Protein from Lampetra japonica, Protects PC12 Cells from Injury Induced by Oxygen-Glucose Deprivation and Reperfusion.

Authors:  Li Lv; Qian Lu; Fangyu Shao; Weiping Li; Qin Zhou; Jihong Wang; Qingwei Li
Journal:  Biomed Res Int       Date:  2016-09-05       Impact factor: 3.411

6.  Coadministration of the FNIII14 Peptide Synergistically Augments the Anti-Cancer Activity of Chemotherapeutic Drugs by Activating Pro-Apoptotic Bim.

Authors:  Takuya Iyoda; Yumi Nagamine; Yoshitomi Nakane; Yuya Tokita; Shougo Akari; Kazuki Otsuka; Motomichi Fujita; Keisuke Itagaki; You-Ichi Takizawa; Hiroaki Orita; Toshiyuki Owaki; Jyunichi Taira; Ryo Hayashi; Hiroaki Kodama; Fumio Fukai
Journal:  PLoS One       Date:  2016-09-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.